Freya Pharma Solutions Announces Response from the FDA on its US Clinical Development Program of LybridoTM for the treatment of Female Sexual Interest/Arousal Disorder
AMSTERDAM, June 19, 2023 /PRNewswire/ — Freya Pharma Solutions, a pharmaceutical company dedicated to developing effective pharmaceutical therapies for women diagnosed with Female Sexual Disorders (FSD), announced today that the United States (US) Food and Drug Administration (FDA) has responded with interest and provided valuable input regarding Freya Pharma’s request for advice on the US Clinical … Read more